Pulmonary arterial hypertension (PAH) is a progressive and fatal lung disease of
multifactorial etiology. Most of the available drugs and FDA-approved therapies for treating …

Background Pulmonary arterial hypertension (PAH) is related to inflammation, and the
lncRNA H19 is associated with inflammation. However, whether PDGF-BB-H19-let-7b-AT 1 …

Pulmonary arterial hypertension (PAH) is a progressive disease defined by an elevation in
pulmonary arterial pressure that can lead to right heart failure and death. Ambrisentan is a …

MircoRNAs (miRNAs) are small non-coding RNAs that govern the gene expression and,
play significant role in the pathogenesis of heart failure. The detection of miRNAs in …

Pulmonary arterial hypertension (PAH) is characterized by endothelial dysfunction and
structural remodeling of the pulmonary vasculature, mediated initially by reduced oxygen …

Pulmonary vascular remodeling and increased arterial wall stiffness are two major causes
for the elevated pulmonary vascular resistance and pulmonary arterial pressure in patients …

Mitogen-Activated Protein Kinase (MAPK)-Activated Protein Kinase 2 (MK2), downstream to
p38MAPK (p38mitogen-activated protein kinase), regulates cellular inflammation and …

Treprostinil (TRE) is a prostanoid analog pulmonary vasodilator drug marketed with
subcutaneous, intravenous (iv), oral, and inhaled routes of administration for the treatment of …

This article describes the preclinical pharmacology and pharmacokinetics (PK) of hexadecyl-
treprostinil (C16TR), a prodrug of treprostinil (TRE), formulated in a lipid nanoparticle (LNP) …

Emotional and psychological difficulties cannot fully be explained by disease‐related factors
in people with pulmonary hypertension (PH). This study examined the relationship between …